The Effect of D,L-6,8-Thioctic acid on the volume of cerebral infarction in ischemic rat modelCerebral Infarction in Ischemic Rat ModelThe effect of D,L-6,8-Thioctic acid on the volume of Cerebral infarction in ischemic rat model

Abstract

Objective : Authors tried to demonstrate neuroprotective effects of antioxidant in reperfusion injury using ischemic rat model and suggest clinical utilization of the antioxidant to ischemic cerebrovascular diseases. Materials and Methods : Rat model was made according to Longa method. 36 Sprague-Dawley rats were used and were equally divided into three groups; (A) treated subcutaneously with D,L-6,8-Thioctic acid 30 minutes before occlusion, (B) within one hour after occlusion, and (C) with vehicle only. Meanwhile, hemodynamic and physiologic parameters were recorded. Neurologic examination was performed immediately and 24 hours after reperfusion. 24 hours after reperfusion, brains were extracted and 2 mm-thickness sections were made and stained with 2% 2,3,5-Triphenyltetrazolim chloride. Then fixed sections were digitalized for calculation of infarction area. Results : There was no significant statistical difference in recorded hemodynamic and physiologic parameters between three groups. The neurologic status taken immediately following reperfusion were (A) 2.67±0.492, (B) 2.75±0.452, and (C) 2.83±0.389, and were improved to (A) 1.67±0.898, (B) 1.92±0.900, and (C) 2.08±0.793 just before sacrificing. However, there was no statistically significant difference between three groups. Mean volume of cerebral infarction was (A) 9.5±1.67%, (B) 10.4±1.58%, and (C) 11.3±1.12% with no significant difference. Any specific correlation between the neurologic status and the mean infarction volume was not observed. Conclusion : Any single agent which affects a certain event of various infarction processes could not reduce the infarction volume. Therefore, the current therapeutic challenge should be the pharmaceutic development of multimechanistic neuroprotectant agents or the selection of synergistic compounds without compromising patients' safety.